Skeletal myoblasts and cardiac repair

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Cell Therapy

Background:

• Cell transplantation in infarcted hearts offers a potential therapeutic strategy for severe heart failure.
• Skeletal myoblasts exhibit favorable characteristics for cell therapy, including autologous origin and ischemia resistance.

Purpose of the Study:

• To evaluate the efficacy of skeletal myoblast transplantation for myocardial tissue repair and improving left ventricular function post-infarction.
• To investigate the underlying mechanisms of cell therapy's benefits, particularly the role of paracrine signaling versus direct cardiomyocyte conversion.

Main Methods:

• Preclinical studies involving skeletal myoblast transplantation in infarcted heart models.
• Early-phase human clinical trials assessing feasibility, safety, and efficacy of cell transfer.

Main Results:

• Skeletal myoblasts demonstrated preservation of left ventricular function and limited adverse remodeling in preclinical models.
• Human trials confirmed the feasibility and safety of myoblast transplantation, despite limited long-term engraftment and poor conversion to cardiomyocytes.
• Key challenges identified include inefficient cell transfer and high early post-transplantation cell death.

Conclusions:

• Skeletal myoblasts and adult stem cells do not effectively repair infarcted myocardium by generating new cardiomyocytes.
• The primary mechanism of benefit likely involves paracrine signaling rather than direct contractile contribution from transplanted cells.
• Further research is needed to overcome current limitations and establish myoblast transplantation as an adjunct therapy for heart failure.